-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5170c Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Program: Oral and Poster Abstracts
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III
Hematology Disease Topics & Pathways:
Research, Health outcomes research, Clinical Research, Education, Real-world evidence, Human, Study Population
Monday, December 9, 2024, 6:00 PM-8:00 PM

Alissa Visram, MD, MPH1, Rajshekhar Chakraborty, MD2, Gregory R Pond, PhD3*, Hsien Seow4*, Anastasia Gayowsky5*, Ghulam Rehman Mohyuddin, MD6, Samer Al Hadidi, MD, MSc7, Alejandro Garcia-Horton8*, Rafael Fonseca, MD9 and Hira Mian, MD10

1Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
2Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
3Department of Oncology, McMaster University, Hamilton, Canada
4Department of Oncology, McMaster University, Hamilton, ON, Canada
5Institute for Clinical Evaluative Sciences, McMaster University, Hamilton, ON, Canada
6Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
7University of Arkansas for Medical Sciences, Little Rock, AR
8McMaster University, Hamilton, ON, CAN
9Division of Hematology, Mayo Clinic, Paradise Valley, AZ
10McMaster University, Hamilton, ON, Canada

Introduction:

With improving overall survival among MM patients, there is an increasing need to both understand the absolute risk and identify risk factors for developing a second primary malignancy (SPM). Understanding these risk and potential modulation factors may help guide decisions regarding treatment options, monitoring surveillance strategies, and patient counselling. Furthermore, understanding this baseline SPM risk will help contextualize the future SPM risk associated with newer therapeutics, including chimeric antigen receptor therapies. Thus, we conducted a population-based study with following objectives: 1) to evaluate the rate and distribution of SPMs, and 2) to identify risk factors including a history of prior malignancy associated with an increased risk of SPMs in patients with MM.

Methods:

We conducted a retrospective population-based study using data from Institute for Clinical Evaluative Sciences (ICES), an administrative database that captures all health records in the publicly funded health care system in Ontario, Canada. Adult patients treated for newly diagnosed MM between 2007-2022 were identified using ICD-O-3 code 9732/3 (MM). The list of secondary cancers (excluding non-melanoma skin cancers) were identified from pathology codes maintained in the Cancer Care Ontario Registry. Additional risk factors were also collected including a history and type of any pre-existing cancer (at least 1 year prior to MM diagnosis), treatment details including history of autologous stem cell transplantation (ASCT) and lenalidomide usage. The Kaplan-Meier method was used to estimate the median overall survival (OS). We estimated the cumulative incidence of secondary cancer accounting for death as a competing risk. To identify the association of prognostic factors on the risk of developing a SPM, we performed competing risks regression and estimated the subdistribution hazard ratios (sHR) accounting for death as a competing risk.

Results:

A total of 12123 patients . The median age at diagnosis was 70 (IQR 61-77) years, 6860 (57%) of our cohort had a male sex. In our 4511 (37%) received at least one ASCT, 8062 (67%) were lenalidomide exposed and 6917 (57%) were cyclophosphamide exposed at any time post MM diagnosis, and 3017 (16%) received oral melphalan based induction regimens. The median follow up for cohort was 4.53 (95% CI 4.4-4.7) years.

A total of 2079 patients (17%) had a prior cancer diagnosis at least 1 year prior to their MM diagnosis. Of these patients, 665 (32%) had received chemotherapy and 553 (27%) had received radiation to treat their prior malignancy. The three most common prior cancers were: prostate cancer (25%), breast cancer (13%) and heme malignancies (4%).The median time from diagnosis of a prior malignancy to MM diagnosis was 6.4 (IQR 2.04-13.26) years.

A total of 1070 (8.8%) of the cohort developed a SPM. The cumulative incidence of SPM post MM diagnosis, accounting for death as a competing risk, was 3.7% at 2 years, 7.6% at 5 years, and 11.5% at 10 years. The three most common SPMs were hematologic (21%), prostate (7%), and lung (7%) cancer. The three most common hematological SPMs were acute myeloid leukemia (37%), B-acute lymphoblastic leukemia (16%), and myelodysplastic syndrome (19%). The median OS following after any SPM diagnosis was 1.64 (95% CI 1.36-1.92) years, was 1.85 (95% CI 1.54-2.28) years for patients that developed a non-hematologic SPM, and was 1.05 (95% CI 0.88-1.40) years for patients that developed a hematologic SPM.

Conclusion:

This study represents one of the largest real-world cohort studies examining the rates, risk factor and outcomes of MM patients developing secondary cancers. We show that a prior malignancy diagnosis increased the risk of SPM after adjusting for ASCT and lenalidomide exposure, sex, and age at MM diagnosis. These data are important for patients and physicians to understand the risks associated with treatment of MM.

Disclosures: Visram: Takeda: Honoraria; Amgen: Honoraria; Janssen: Honoraria, Research Funding; Sanofi: Honoraria; Forus Therapeutics: Honoraria; BMS: Honoraria, Research Funding; GSK: Honoraria. Chakraborty: Janssen: Consultancy; Sanofi: Consultancy; Adaptive: Consultancy. Pond: Astra-Zeneca: Consultancy; Merck: Consultancy; Profound Medical and Traferox: Consultancy; Roche: Current equity holder in publicly-traded company; Takeda: Honoraria. Mohyuddin: MashupMD: Honoraria; Medscape: Honoraria; Janssen: Research Funding. Al Hadidi: Sanofi: Consultancy; Pfizer: Consultancy; Janssen: Consultancy. Fonseca: Antengene: Membership on an entity's Board of Directors or advisory committees; Patent for FISH in MM - ~$2000/year: Patents & Royalties: Patent for FISH in MM - ~$2000/year; Celgene, Bristol Myers Squibb, Bayer, Amgen, Janssen, Kite, a Gilead company, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi, OncoTracker: Honoraria; AbbVie, Adaptive, Amgen, Apple, Bayer, BMS/Celgene, Gilead, GSK, Janssen, Kite, Karyopharm, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Arduro Biotech, Oncotracker, Oncopeptides, Pharmacyclics, Pfizer, RA Capital, Regeneron, Sanofi: Consultancy. Mian: BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria.

*signifies non-member of ASH